If it is an effective treatment for just bile duct cancer, than that is worth heaps alone!
But even if imu shifts focus more to onCARlytics, that's ok.
NEU has become an asx biotech darling. But their initial focus was a drug called Glypromate. But that failed a phase 3, and hit the scrap heap. Then the focus was nnz2566 for traumatic brain injury, and again another failed clinical trial.
But neu have learnt and adapted, and are now a great success.
